A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC's leading position in ...

This is exemplified by granted US patent US11,517,582, which covers the use of CRISPR-Cas systems to achieve selective killing of bacteria by at least 1000-fold in situations where bacteria are ...

The pharmaceutical industry remains a hub of patent innovation ... its way into clinical trials in the mid-2000s. In 2014, ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.